Insights
Media Center
Latest Therapy Updates
- Izalontamab brengitecan approved for esophageal squamous cell carcinoma
- Novartis’s radioligand therapy drug Pluvicto® is approved in China for a new indication in the treatment of patients with metastatic hormone-sensitive prostate cancer
- A Chance for Disease-Free Survival: Fudan Team’s Findings Published in The Lancet
- First International Patient to Receive Solid-Tumor CAR-T Therapy in China Discharged from Jiahui International Cancer Center
- Tagrisso® combined with Orpathys® showed statistically and clinically significant improvements in progression-free survival and overall survival in patients with lung cancer who had disease progression after Tagrisso® treatment and had MET-driven drug-resistant EGFR mutations.
Page 2 of 12
What could this mean for your care?
A promising treatment raises a personal question: could it be an option for you? Chirona helps you explore that question with the right specialists.
Start a case reviewHow our service worksUnderstand your options
Explore the treatments relevant to your diagnosis, previous care and priorities.
Bring your case to specialists
We help organise your medical records and coordinate a professional assessment of suitability and access.
Plan the next step together
If a treatment path is appropriate, we help coordinate consultations, hospital arrangements and continuity of care.